The trial concluded there was no difference in the frequency of MACCE
at hospital discharge.
The major findings of this study were as follows: (1) all these IR indexes were able to risk-stratify patients and predict 2-year composite adverse cardiovascular events after PCI; (2) only clinical rSS was an independent predictor of 2-year mortality; (3) clinical rSS had superior predictability of 2-year all-cause death than other two anatomic rSS and SRI, whereas rSS was superior in predicting repeat revascularization than clinical rSS and SRI; and (4) IR level of rSS ≥ 8 and SRI <70% had same predictability of 2-year all-cause death, repeat revascularization, and MACCE
In this study, at the 36-month period, the all-cause mortality and MACCE
were compared using GRC in patients undergoing CABG and PCI treatment with LMCA lesion and 3VD.
Overall, 11 patients died (8%) and 26 (18%) experienced MACCE
(11 deaths, 3 AMI, 10 PCI, and 2 strokes).
Patients within the [SxSII.sub.High] tertile had a significantly higher incidence of all-cause mortality, MACE, and MACCE
compared with patients in lower tertiles (Table 4).
In all CAD patients, rs5277 C allele carriage increased hazard of long-term MACCE
after CABG (HR: 1.561; 95% CI: 1.0272.375; p = 0.037).
Three studies investigated the association between smoking and MACCE
and significant association was found (OR: 2.09, 95% CI: 1.433.06; I2 = 21.6%).
All patients were observed after the procedure while in the hospital for any adverse clinical outcomes like hospital major adverse cardiac cerebral events (MACCE
) including all-cause death new onset myocardial infarction and stroke.
The mean in-hospital MACCE
rate was 1.3% [+ or -] 1.9% (range: from 0,0% to 5.6%) with relatively high MACCE
rates shown by Katz et al.
They designed a retrospective cohort study of 371 patients diagnosed with OSA (AHI [greater than or equal to] 15 [h.sup.-1]) who subsequently underwent a PCI and evaluated cardiac death, general mortality, major adverse cardiac events (MACE) (severe angina, myocardial infarction, PCI, coronary artery bypass grafting, or death), and major adverse cardiac or cerebrovascular events (MACCE
The primary endpoint is defined as successful device implantation without in-hospital major adverse cardiovascular or cerebrovascular events (MACCE
) through discharge or seven days post-procedure (whichever comes first).
The procedure was found to be safe, the company reported, and there were no new major adverse cardiac or coronary events (MACCE
) reported between the six and 18 month follow-up.